Ketamine is a mixture of two forms, S(+) ketamine and R(-) ketamine. It has been FDA approved since 1968 as an anesthetic. It is now a generic and although numerous studies have shown it helps treatment resistant depression, it will never be FDA approved since there is no financial incentive for the pharmaceutical industry to pursue.

​

Shrink Savannah, has been experiencing success with treating certain patients with ketamine infusions for their severe depression since 2017. Our medical staff and technicians are here to help you determine if you are a candidate for this treatment. Please fill out the form to the right.

​

The anesthetic ketamine has been a popular drug for decades due to its ability to put users in a blissful mood. In the Spring of 2017, the American Psychiatric Association released a consensus statement acknowledging that the drug might also be a breakthrough treatment for severe depression.

​

The statement authors write that seven studies--all placebo-controlled, double-blind, and randomized--provide evidence that ketamine therapy is a "rapid and robust, albeit transient" response to severe clinical depression. The treatment is effective within hours, while conventional antidepressants generally take weeks to work. The transient nature of the drug, meanwhile, suggest it works best with twice-weekly dosing.

​